StemRIM (TYO:4599) has amended the protocol for the global late-stage phase two clinical trial of Redasemtide for the treatment of acute ischemic stroke (AIS), according to a Monday filing with the Tokyo Stock Exchange.
The change includes adding a new group of patients who have undergone endovascular recanalization therapy to the study.
The biotechnology company will also relax the eligibility criteria for the participating patients without significantly extending the trial period.
The company said the move aims to address changes in the treatment paradigm for AIS and the rise in the number of eligible patients.
Price (JPY): $345.00, Change: $-5.0, Percent Change: -1.43%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.